Cannabis Law Report

APRIL 1, 2022

Not only is it the second British cannabis company to go public in as many weeks , but Celadon is the second homegrown cannabis company ever to list on AIM, following GW Pharmaceuticals in 2001. Admission . The newly formed entity now has 61.7m ordinary shares in issue, giving it a market capitalisation at admission of £97.4

Chronic Pain 52

Chronic Pain Pharmaceutical Sativa Business 52

Puff Puff Post

DECEMBER 12, 2018

Dr. Mark Ware, who practises pain medicine in Montreal and has spent 20 years researching chronic pain, will be arguing for the use of medical cannabis for conditions such as neuropathic pain and chemotherapy-induced nausea and vomiting.

Patients 76

Patients Research and Development Conditions Chronic Pain 76

CannaTech

SEPTEMBER 16, 2018

Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.

Education 66

Education Medicine Clinical Trials Patients 66

Puff Puff Post

JUNE 5, 2019

This brought the legislative act known as the Medical Marijuana Access and Resources (MMAR) into legislature on July 30 th , 2001 permitted patients access to cannabis for medicinal purposes, from Licensed Producers approved by Health Canada.

Medicine 96

Medicine Patients Cannabinoids Oil 96

Dr. Michele Ross

DECEMBER 11, 2018

The National Fibromyalgia and Chronic Pain Association completed a survey on the impact on patients of changing hydrocodone from Schedule 3 to Schedule 2. Nabilone for the treatment of pain in fibromyalgia. J Pain, 2008. PLoS One, 2001. No research has suggested harm from using cannabis in fibromyalgia patients.

Research and Development 66

Research and Development Therapy Patients Treatment 66

Sensi Seeds

JANUARY 4, 2019

Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). Context of the Medicinal Cannabis Situation.

Medicine 75

Medicine Research and Development Patients Programs 75

Cannabis Law Report

JULY 12, 2019

As reported in the Guardian, Analytical Cannabis emphasises the importance of this for those suffering from conditions such as chronic pain, epilepsy and neurological and psychiatric disorders who have long been seeking access to what they hope is a transformative medicine. Prospect of a wider legalisation of cannabis in the UK?

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

AUGUST 16, 2019

Some Empire State doctors have begun advocating for expanding the program as a safer alternative than opiates for treating chronic pain. Two Commerce Square, 2001 Market Street, Suite 3100. New York’s medical marijuana program has approximately 102,000 patients. Pennsylvania Expands Medical Marijuana Program. Patrick McKnight.

Legalization 45

Legalization Programs Decriminalization Chronic Pain 45

Puff Puff Post

SEPTEMBER 24, 2019

On July 30 th , 2001, the government brought this into a legislative act known as the Medical Marijuana Access and Resources (MMAR). Acute and chronic pain (i.e. fibromyalgia, pain from motor vehicle accidents, and pain due to various types of cancer), . Kaempferol. Cannabis for Potential Medicinal Purposes .

History 94

History Cannabinoids Indica Tincture 94

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Only one article appeared in the MJA in 2000 and again in 2001. Conclusions. This offers a more denotative approach to complement the data.

Research and Development 52

Research and Development Medicine Access Media 52

Ellementa

SEPTEMBER 1, 2019

A lot of “female pain” and discomfort can be addressed by cannabis including: ? Inflammatory pain: Arthritis, Fibromyalgia, MS, Crohn’s, IBS. ? Injury pain, chronic pain, repetitive stress pain, “tech neck”. ? Normal wear and tear from aging”: joint, ligament and muscle pain.

CBD 63

CBD Terpenes Chronic Pain Cannabinoids 63

The Cannigma

JANUARY 13, 2023

10 A 2001 review paper by cannabis researcher Dr. Ethan Russo details the historical use of cannabis for migraines. However, they may have a role in chronic pain conditions when used as a maintenance treatment, with vaporizing added on for abortive use during migraine attacks.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

OCTOBER 20, 2019

For example, there is a growing body of evidence that marijuana is working for chronic pain. Whether or not the pharmaceutical industry can produce a substance they can call a drug that would be approved for a pain indication remains the question,” [xiv]. marijuana companies. Westwood, and J. Kleignen, 2015. JAMA 313: 2474-2483.

Marijuana 45

Marijuana Pharmaceutical Chronic Pain Research and Development 45

Cannabis Law Report

MAY 14, 2019

Escalating numbers of people in the UK are being given highly addictive painkillers for chronic pain in spite of evidence pointing that they become ineffective after just a few days. It recommended moving cannabis from Schedule B to Schedule 2 of the Misuse of Drugs Regulations 2001, which means it can be prescribed.

Research and Development 45

Research and Development Chronic Pain Epilepsy Medicine 45

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma.

Law 40

Law Seed-To-Sale Hemp Recreational 40